Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

Por Ou, Sai-Hong Ignatius, Socinski, Mark A, Gadgeel, Shirish, Gandhi, Leena, West, Howard, Chiappori, Alberto Alejandro, Cohen, Victor, Riely, Gregory J, Smoljanovic, Vlatka, Bordogna, Walter, Wright, Elaine, Debusk, Kendra, Zeaiter, Ali, Shaw, Alice T
Publicado no ESMO Open (2018)